ライフサイエンスコーパス: CypA

1 CypA (Cyclophilin A) is a peptidyl-prolyl isomerase prev

2 CypA antagonists, such as cyclosporines, are potent inhi

3 CypA binds to HCV's nonstructural protein (NS)5A to prom

4 CypA can either promote or inhibit viral infection, depe

5 CypA inhibitors prevented replication of residual HCV in

6 CypA interacts with its substrate via conformational sel

7 CypA modulates HIV-1 virion core detection by this class

8 CypA recognizes specific geometries of the curved lattic

9 CypA was previously reported to be required for the bioc

10 cting HIV-1 at an early post-entry step by a CypA-dependent mechanism.

11 yclophilin A (CypA) chimera resulting from a CypA retrotransposition between exons 7 and 8 of the TRI

12 However, a CypA-independent HCV variant had reduced replication in

13 nemestrina and M. fascicularis identifies a CypA retrotransposition in the 3' untranslated region of

14 ng interaction between MDM2 and p53-72R in a CypA-dependent manner.

15 These studies reveal that a CypA-mediated conformational change within the PRLr/Jak2

16 of developing AADs, whereas treatment with a CypA inhibitor attenuates aortic dilation by 56% (P = 0.

17 el protein systems, including cyclophilin A (CypA) and the minor allele variant of human alanine:glyo

18 hexamers and in complex with cyclophilin A (CypA) at near-atomic resolutions.

19 The peptidyl-prolyl isomerase cyclophilin A (CypA) binds a proline-rich loop on the surface of HIV-1

20 The host cell protein cyclophilin A (CypA) binds to CA of human immunodeficiency virus type 1

21 ably, in Owl monkeys (omk), a cyclophilin A (CypA) cDNA has been transposed into the TRIM5 locus, res

22 mediated by TRIMCyp, a TRIM5-cyclophilin A (CypA) chimera resulting from a CypA retrotransposition b

23 ve site of the dynamic enzyme cyclophilin A (CypA) has been previously linked to its catalytic functi

24 Cyclophilin A (CypA) has interacted with the CA of lentiviruses related

25 ex in which HCV NS5A and host cyclophilin A (CypA) have been shown to be present together with the vi

26 f the CA-binding host protein cyclophilin A (CypA) inhibited HIV-1 uncoating and reduced the stimulat

27 visna virus (MVV) Vif hijacks cyclophilin A (CypA) instead.

28 The host cell factor cyclophilin A (CypA) interacts directly with the HIV-1 capsid and regul

29 d in cell lines indicate that cyclophilin A (CypA) is a component of HIV type 1 (HIV-1) virions, and

30 Cyclophilin A (CypA) is a member of a family of cellular proteins that

31 Cyclophilin A (CypA) is an intracellular protein that is proinflammator

32 th the human prolyl isomerase cyclophilin A (CypA) is essential for viral RNA replication.

33 cis-trans isomerase (PPIase) cyclophilin A (CypA) is hijacked by Listeria at membrane protrusions us

34 Cyclophilin A (CypA) is required for viral replication, and CypA inhibi

35 n mediated by owl monkey TRIM-cyclophilin A (CypA) or human TRIM5alpha.

36 Recent studies showed that cyclophilin A (CypA) promotes NF-kappaB/p65 nuclear translocation, resu

37 Host factor protein Cyclophilin A (CypA) regulates HIV-1 viral infectivity through direct i

38 yl prolyl cis/trans isomerase cyclophilin A (CypA) serves as a cellular receptor for the important im

39 Herein, we identify a novel Cyclophilin A (CypA) small molecule inhibitor (HL001) that induces non-

40 otif-containing 5 (TRIM5) and cyclophilin A (CypA) that potently blocks HIV-1 infection.

41 The binding of cyclophilin A (CypA) to the human immunodeficiency virus type 1 (HIV-1)

42 ding of the host cell protein cyclophilin A (CypA) to the viral capsid protein (CA).

43 We found that cyclophilin A (CypA) was excluded from wild-type SIV particles but was

44 eractions with both CPSF6 and cyclophilin A (CypA) were essential for the unique dose-response curve.

45 Also, virion incorporation of cyclophilin A (CypA), a cellular peptidyl-prolyl isomerase that binds s

46 Cyclophilin A (CypA), a cytoplasmic, human immunodeficiency virus type

47 tin, ribonuclease A (RNaseA), cyclophilin A (CypA), and bovine carbonic anhydrase II (BCAII).

48 tin, ribonuclease A (RNaseA), cyclophilin A (CypA), and bovine carbonic anhydrase II (BCAII).

49 20-kDa protein, identified as cyclophilin A (CypA), and CypA was present on the surface of Hc yeasts.

50 al inhibition or silencing of cyclophilin A (CypA), as well as CA mutant viruses, we implicated CypA

51 d with host cell factors like cyclophilin A (CypA), can influence the efficiency of reverse transcrip

52 viral lifecycle by utilising cyclophilin A (CypA), cleavage and polyadenylation specificity factor-6

53 essential cellular co-factor cyclophilin A (CypA), HCV RNA replication is markedly diminished, provi

54 ablation and/or inhibition of cyclophilin A (CypA), here we show that expression of APOE4 and lack of

55 cs simulations to study human cyclophilin A (CypA), in order to understand the role of enzyme motions

56 ificity factor 6 (CPSF6), and cyclophilin A (CypA), indicating that the observed loss of sensitivity

57 ects of the host cell protein cyclophilin A (CypA), which binds to HIV-1 CA, on HIV-1 infection of no

58 ptidyl-prolyl isomerase (PPI) cyclophilin A (CypA), which is implicated in the regulation of protein

59 9), I(223), and M(228) in the cyclophilin A (CypA)-binding loop in B57(+) individuals with progressiv

60 tor 6 (CPSF6), as well as the cyclophilin A (CypA)-binding loop mutation P90A, all increase sensitivi

61 passes residues implicated in cyclophilin A (CypA)-dependent HCV RNA replication.

62 1 (HIV-1) CA binding protein cyclophilin A (CypA).

63 to the HIV-1 binding protein Cyclophilin A (CypA).

64 es host cell factors, such as cyclophilin A (CypA).

65 ype controls through secreted cyclophilin A (CypA).

66 interaction with target cell cyclophilin A (CypA).

67 n via robust up-regulation of cyclophilin A (CypA).

68 essential host factors, like cyclophilin A (CypA).

69 ion with the cellular protein cyclophilin A (CypA).

70 interacting with host factor cyclophilin A (CypA).

71 by targeting a host protein, cyclophilin A (CypA).

72 Cyclophilin A (CypA, encoded by Ppia) is highly expressed in vascular s

73 or residues 66 and 143 in the cyclophilin A [CypA] domain) confer restriction specificity.

74 CsA abolished CypA-Vpr binding but had no effect on induction of G2 ar

75 In addition, CypA and its enzyme family have been found to play criti

76 Because core-binding factor subunit beta and CypA are both highly conserved among mammals, the requir

77 which showed decreased binding to CPSF6 and CypA in IFN-beta-treated cells.

78 he known binding interaction between CsA and CypA was detected using both the MALDI- and LC-MS-based

79 ein, identified as cyclophilin A (CypA), and CypA was present on the surface of Hc yeasts.

80 ample containing NS5B(Delta21), NS5A-D2, and CypA specifically inhibits the interaction between CypA

81 We show that both NS5B(Delta21) and CypA share a common binding site on NS5A that contains r

82 ch concluded that beta-hairpin formation and CypA-binding are energetically independent events.

83 A comparative analysis of Fv1Cyp and CypA binding to a preformed HIV-1 CA lattice reveals how

84 molecular interplay between NS5B, NS5A, and CypA, three essentials proteins for HCV replication.

85 bunit 6 (CPSF6) and cyclophilins (Nup358 and CypA), respectively, cannot replicate in primary human m

86 bound to the viral replication proteins, and CypA and Roc1 also bound to the viral RNA.

87 CypA) is required for viral replication, and CypA inhibitors are in development.

88 The interaction between Vpr and CypA is intriguing, and further studies should examine i

89 ization of the surrounding prolines that are CypA substrates and by substitutions conferring resistan

90 pecifically inhibits the interaction between CypA and NS5A-D2 without altering the one between NS5A-D

91 ermolecular hydrophobic interactions between CypA and the substrate, an intricate enzyme-substrate in

92 s of active site residues of substrate-bound CypA is inherent in the substrate-free enzyme.

93 nimal(21) and inhibition of such activity by CypA has not been detected(27).

94 This activity required capsid binding by CypA and correlated with CypA linkage to the TRIM5a caps

95 HIV-1 CA is similarly greeted by CypA soon after entry into rhesus macaque or African gre

96 for TNPO3 in HIV-1 infection is modulated by CypA-CA interactions.

97 human TRIM5alpha orthologue is precluded by CypA.

98 d the mechanism of capsid pattern sensing by CypA.

99 dependent of the well-characterized HIV-1 CA-CypA interaction.

100 Disruption of the CA-CypA interaction decreases HIV-1 infectivity in human ce

101 striction activity, particularly when the CA-CypA interaction is disrupted.

102 vity was not altered by disruption of the CA-CypA interaction or by elimination of CypA protein.

103 ls, we demonstrate that disruption of the CA-CypA interaction renders HIV-1 susceptible to potent res

104 wer drug concentrations upon blocking the CA-CypA interaction suggests a protective role for CypA aga

105 entered the cytoplasm, but only when the CA-CypA interaction was disrupted.

106 depending on the capsid and the target cell, CypA-CA binding either stabilized or destabilized the ca

107 urring HIV-1 variant exists that circumvents CypA dependence in human cells.

108 Vif to bind zinc ion, Cul5, and the cofactor CypA.

109 Collectively, CypA dually exerts pro-osteogenic and anti-osteoclastic

110 g ability of a retrotransposed CyclophilinA (CypA), resulting in novel antiviral specificity against

111 mains 2 and 3 of NS5A (NS5A-D2 and NS5A-D3), CypA, and NS5B(Delta21).

112 ROS-dependent CypA secretion by ECs is an important signaling mechanis

113 In Jurkat T lymphocytes, disrupting CypA-CA interaction either by cyclosporine (Cs) treatmen

114 The structure exhibits a distinct CypA-binding pattern in which CypA selectively bridges t

115 tidyl-prolyl isomerase A (PPIA) that encodes CypA on HCV infection and replication of human hepatocyt

116 The re-expression of an exogenous CypA escape protein, which contains escape mutations at

117 As expected, CypA depletion had no additional effect on the behavior

118 VSMC-derived intracellular and extracellular CypA are required for ROS generation and matrix metallop

119 ne motif in the helix 4-5 loop important for CypA binding; instead, the helix 4-5 loop in these SIVs

120 Antagonism of the extracellular receptor for CypA (CD147) also reduced acetaminophen-induced liver in

121 A interaction suggests a protective role for CypA against high concentrations of PF74.

122 Our results demonstrate a crucial role for CypA during Listeria infections.

123 ata define a previously undescribed role for CypA in AAA formation and suggest CypA as a new target f

124 le in HIV-1 CA assemblies in the escape from CypA dependence, by magic-angle spinning (MAS) NMR and m

125 a determining factor in HIV-1's escape from CypA dependence.

126 ons hampers the microbes from spreading from CypA null cells.

127 However, F/TE from CypA-silenced yeasts still inhibited binding of wild-typ

128 d the dynamics profiles of the A92E and G94D CypA escape mutants closely resemble that of wild-type C

129 R spectra of wild-type and the A92E and G94D CypA escape mutants, we demonstrate that assembled CA is

130 Silencing of Hc CypA by RNA interference reduced yeast binding to DC by

131 ctroscopy between HCV NS5B(Delta21) and host CypA.

132 ) has been known for nearly two decades, how CypA interacts with the viral capsid and modulates HIV-1

133 These results provide new insights into how CypA stabilizes the HIV-1 capsid and is recruited to fac

134 orescence polarization-based assay for human CypA that can be adapted to high-throughput screening fo

135 bitor modeled after AoT5Cyp, by fusing human CypA to human TRIM5 (hT5Cyp).

136 el vif-sensitive antiviral activity of human CypA that may limit zoonotic transmission of SIV and the

137 eled cyclosporin A analog and purified human CypA to quantitatively measure the binding capacity of u

138 as well as CA mutant viruses, we implicated CypA in the SUN2-imposed block to HIV infection.

139 of the SP1 tail, the functionally important CypA loop, and the loop preceding helix 8 are modulated

140 show that many alternative conformations in CypA are populated only at 240 K and above, yet others r

141 Vpr expression in CypA-/- cells leads to induction of G2 arrest in a manne

142 pecific PCR revealed DNA hypermethylation in CypA-KD P19 cells, as the normally unmethylated paternal

143 x9 and Runx2 were all significantly lower in CypA knockdown chondrogenic cells than in wild-type cell

144 ne methylation leads to silencing of Peg3 in CypA-KD P19 cells.

145 ication flow through the distinct regions in CypA and, therefore, as targets for future mutational st

146 anner that is indistinguishable from that in CypA+ cells.

147 es than in other cell types, we investigated CypA and CsA activities in HIV-1-infected primary human

148 ell types, demonstrating that this rescue is CypA dependent.

149 ion of phenotype in cyclophilin A knockdown (CypA-KD) P19 cells, we observed a silent paternally expr

150 Our data demonstrated that mice lacking CypA (Ppia(-/-)) were resistant to acetaminophen toxicit

151 e a TRIMCyp chimera containing a full-length CypA.

152 is required during uncoating for maintaining CypA-CA interaction, which promotes optimal stability of

153 support HCV replication, finding that murine CypA only partially rescued viral replication in Huh7.5-

154 Newborn CypA-deficient pups double stained with alcian blue and

155 We thus compared the ability of CypA from mouse, tree shrew, and seven non-human primate

156 icted phenotype also restored the ability of CypA-restricted HIV-1 mutants to infect growth-arrested

157 s observed between the levels or activity of CypA and the extent of PRL-induced signaling and gene ex

158 r the isomerase or the chaperone activity of CypA to replicate in hepatocytes and that CypA is the pr

159 r the hydrophobic pocket binding activity of CypA.

160 ransformed cells and show that the amount of CypA incorporated into virions is variable and that CsA

161 In contrast, reduction of the binding of CypA to HIV-1 capsids in Jurkat T lymphocytes resulted i

162 Reducing the binding of CypA to the A92E mutant capsid, either by Cs treatment o

163 es as a ligand for DC VLA-5, that binding of CypA to VLA-5 is at a site different from FN, and that t

164 rCypA did not further inhibit the binding of CypA-silenced yeasts to DC.

165 e amplification and the independent birth of CypA gene fusions in various primate species.

166 nally important alternative conformations of CypA, confirming earlier synchrotron-based results.

167 e evidence for the important contribution of CypA as a pertinent component acting through NF-kappaB-S

168 ission of SIV and the first demonstration of CypA encapsidation into a virus other than human immunod

169 , and F/TE from wild-type yeasts depleted of CypA also inhibited yeast binding to DC.

170 Cores isolated from WT virus depleted of CypA had an unstable-core phenotype, confirming a role o

171 their proper formation, as cells depleted of CypA have extended actin-rich structures that are missha

172 or by RNA interference-mediated depletion of CypA expression in target cells.

173 Conversely, the stimulatory effect of CypA on HIV-1 infectivity was completely independent of

174 Importantly, the inhibitory effect of CypA was restricted to virus-producing cells and was TRI

175 Here the effects of CypA and TRIM5alpha on HIV-1 restriction were examined d

176 HC) analyses further verified the effects of CypA deficiency on chondrogenic differentiation.

177 However, the effects of CypA on osteoclast activity and bone maintenance are ent

178 the CA-CypA interaction or by elimination of CypA protein.

179 es of SIVagm Vif to inhibit encapsidation of CypA and to increase viral infectivity were shared by rh

180 e we compare the conformational ensembles of CypA by multitemperature synchrotron crystallography and

181 Exclusion of CypA from SIVagm particles was not associated with intra

182 demonstration of the epigenetic function of CypA in protecting the paternal allele of Peg3 from DNA

183 1 transduction of these cells independent of CypA.

184 Infection of CypA knockout Jurkat cells or treatment of Jurkat cells

185 tion network, connectivity, and influence of CypA residues upon substrate binding, mutation, and duri

186 emonstrates that pharmacologic inhibition of CypA offers a potential therapeutic strategy via specifi

187 Pharmacological inhibition of CypA rescues PKR from antagonism by HCV NS5A, leading to

188 Knockdown of CypA in ECs abolished the increase in vascular smooth mu

189 We reduced levels of CypA in these cells using small hairpin RNAs (shRNAs).

190 In osteoclasts, loss of CypA activates BtK (Bruton's tyrosine kinase) and subseq

191 Thus, modulation of CypA may be useful in future efforts targeting osteoporo

192 A catalytically inactive mutant of CypA was also able to inhibit TBSV replication in vitro

193 Overexpression of CypA and its mutant in yeast or plant leaves led to inhi

194 ues that reside in the hydrophobic pocket of CypA where proline-containing peptide substrates and cyc

195 and glutamine 111 in the catalytic pocket of CypA.

196 The presence of CypA in vif-defective SIVagm was correlated with reduced

197 Surprisingly, the presence of CypA or its binding to Vpr is dispensable for the abilit

198 n of the speedup in rates in the presence of CypA, which is in notable agreement with experimental es

199 RNA interference-mediated reduction of CypA expression enhanced the permissiveness of HeLa cell

200 lve the long-standing mystery of the role of CypA in HIV-1 replication by demonstrating that this ubi

201 nstable-core phenotype, confirming a role of CypA in promoting optimal core stability.

202 In this report, we unveil the role of CypA in signal-induced chondrogenic differentiation and

203 e cells) and aortas had greater secretion of CypA both at baseline and in response to Ang II stimulat

204 Overexpression and gene silencing of CypA verified osteogenic and anti-osteoclastic effects.

205 the retroviral capsid-binding specificity of CypA.

206 We determined the cryoEM structure of CypA in complex with the assembled HIV-1 capsid at 8-A r

207 Although the crystal structure of CypA in complex with the N-terminal domain of the HIV-1

208 Treatment of CypA-KD P19 cells with the DNA demethylating agent 5-aza

209 ts in nondividing cells that is dependent on CypA-CA interactions.

210 odulate the dependence of HIV-1 infection on CypA.

211 duced dependence of the compensated virus on CypA that is normally essential for optimal infectivity.

212 Thus, EBOV does not depend on (CypA) for replication, in contrast to many other viruses

213 at the loss of CA interactions with CPSF6 or CypA leads to higher IFN sensitivity.

214 In osteoblasts, CypA is necessary for BMP-2 (Bone Morphogenetic Protein-

215 The PPIase CypA colocalizes with the Parkinson's disease (PD)-assoc

216 Loss of PRLr-CypA binding, following treatment with the PPI inhibitor

217 riants in PPIA that destabilize its product, CypA, and prevent HCV infection and replication.

218 BB breakdown by activating a proinflammatory CypA-nuclear factor-kappaB-matrix-metalloproteinase-9 pa

219 In mice, Tgfbr1(iko) rapidly promotes CypA production in SMCs of developing AADs, whereas trea

220 titis C virus (HCV) co-opts the host protein CypA to aid evasion of antiviral responses dependent on

221 pistatic to both TRIM5alpha and the putative CypA-regulated restriction factor.

222 We found that recombinant CypA, Roc1, and Roc2 strongly inhibited TBSV replication

223 Strikingly, we reveal a second CypA-binding site formed by the hydrophobic sequence (47

224 ly rescued viral replication in Huh7.5-shRNA CypA cells.

225 Here, we simulate CypA using multiple-microsecond-long atomistic molecular

226 e CypA-binding pattern is achieved by single-CypA molecules simultaneously interacting with two CA su

227 d role for CypA in AAA formation and suggest CypA as a new target for treating cardiovascular disease

228 In summary, CypA is a DAMP that mediates acetaminophen poisoning.

229 the molecular details of the alpha-synuclein/CypA interaction.

230 some SIV lineages to evolve means other than CypA binding to stabilize the capsid.

231 -sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-alpha-induced blo

232 might be resistant to HCV infection and that CypA is a good therapeutic target.

233 of CypA to replicate in hepatocytes and that CypA is the principal mediator of the Cyp inhibitor anti

234 We conclude that CypA can fine-tune the dynamic ensemble of the disordere

235 cells further supported the conclusion that CypA is needed for chondrogenic differentiation.

236 of tombusvirus replication, confirming that CypA is a restriction factor for TBSV.

237 These data demonstrate that CypA serves as a ligand for DC VLA-5, that binding of Cy

238 We hypothesized that CypA is released from necrotic liver cells and acts as a

239 These results indicate that CypA-restricted mutants are specifically impaired at a s

240 or destabilized the capsid, indicating that CypA modulates HIV-1 capsid disassembly.

241 lls than in wild-type cells, indicating that CypA plays a functional role in chondrogenic differentia

242 observations argue against the proposal that CypA binding is coupled with beta-hairpin formation and

243 Additional in vitro studies revealed that CypA, Roc1, and Roc2 cyclophilins bound to the viral rep

244 Using shRNAs, we showed that CypA was required for replication of HCV in Huh-7.5 cell

245 NMR spectroscopy shows that CypA catalyzes isomerization of proline 128 in the C-ter

246 Our data suggest that CypA is a key target for treating APOE4-mediated neurova

247 These results suggest that CypA loop dynamics is a determining factor in HIV-1's es

248 Genetic and biochemical data suggest that CypA protects HIV-1 from a CA-specific restriction facto

249 th previous reports, these data suggest that CypA protects HIV-1 from an unknown antiviral activity i

250 The CypA loop in assembled wild-type CA from two strains exh

251 is located between the beta-hairpin and the CypA-binding loop.

252 22-26) pointed to human TRIM5alpha being the CypA-sensitive restriction factor.

253 The variants appeared to destabilize the CypA protein; the single amino acid changes led to rapid

254 ation, demonstrating the specificity for the CypA requirement.

255 that is partially overcome by changes in the CypA-binding loop and identify a mechanism for an HIV-1

256 ntified two mutations, A92E and G94D, in the CypA-binding loop of CA that confer the ability of HIV-1

257 The complexes included the CypA-cyclosporin A complex and the BCAII-4-carboxybenzen

258 TRIM5alpha binding interface at or near the CypA binding loop of CA.

259 pharmacological or genetic disruption of the CypA-CA interaction or by RNA interference-mediated depl

260 Disruption of the CypA-CA interaction, either by mutation of the CA residu

261 A second-site suppressor of the CypA-restricted phenotype also restored the ability of C

262 The 1.38 angstrom crystal structure of the CypA/PreNAC complex displays a contact between alanine 5

263 Only the CypA knockdown drastically decreased HCV replication.

264 ts indicate that CA determinants outside the CypA-binding loop can modulate the dependence of HIV-1 i

265 Remarkably, the CypA loop dynamics of wild-type CA HXB2 assembly is sign

266 ecreted APOE3, but not APOE4, suppressed the CypA-nuclear factor-kappaB-matrix-metalloproteinase-9 pa

267 and solid-state NMR further reveal that the CypA-binding pattern is achieved by single-CypA molecule

268 ine-35 of Vpr as well as incubation with the CypA inhibitor cyclosporine A (CsA).

269 nstructs, we illustrate the ability of these CypA loop changes to partially restore replication of th

270 Remarkably, these CypA mutants fail to restore HCV replication, suggesting

271 ppressive analogs bind with high affinity to CypA and inhibit HIV-1 replication.

272 reduced binding of CD147-derived peptides to CypA and also diminished transport of CD147 to the plasm

273 isolates and determines their sensitivity to CypA inhibitors.

274 ive at inhibiting leukocyte migration toward CypA in vitro as well as in the recruitment of leukocyte

275 TRIM-CypA is an owl monkey-specific variant of the retrovirus

276 teasome inhibition prevented owl monkey TRIM-CypA restriction of HIV-1 reverse transcription, even th

277 (OMK) cell assay that is based on timed TRIM-CypA-mediated restriction of HIV-1 replication.

278 losporine (CsA) washout assay, in which TRIM-CypA-mediated restriction of viral replication is used t

279 However, while TRIM-CypA restriction is partly dependent on a RING domain, r

280 tivation and HIV-1 restriction by the Trim12-CypA fusions were inhibited by disruption of TAK1.

281 The three Trim12-CypA fusions all activated AP-1 and restricted HIV-1 tra

282 icted HIV-1 transduction, whereas the Trim30-CypA fusions did neither.

283 nimals coexpressing the TRIM5(TFP) and TRIM5(CypA) alleles took significantly longer to become infect

284 ocus, resulting in the expression of a TRIM5-CypA fusion protein (TRIMCyp) that restricts retroviral

285 ) and multiple, independently derived, TRIM5-CypA fusion genes(4,5,15,22-26) pointed to human TRIM5al

286 In Fv1Cyp, two CypA moieties are located at opposing ends, creating a m

287 B2 assembly is significantly attenuated upon CypA binding, and the dynamics profiles of the A92E and

288 In humans, urinary CypA concentration was significantly increased in patien

289 resent study, we examine the role of the Vpr-CypA interaction on Vpr-induced G2 arrest.

290 ost inflammatory response was increased when CypA was injected with necrotic liver.

291 of HIV type 1 (HIV-1) virions, and that when CypA incorporation into virions is inhibited by treatmen

292 its a distinct CypA-binding pattern in which CypA selectively bridges the two CA hexamers along the d

293 that the HCV NS5B polymerase associates with CypA via its enzymatic pocket.

294 We find that Vpr coimmunoprecipitates with CypA and that this interaction is disrupted by substitut

295 luorescence polarization in combination with CypA is highly advantageous for the accurate assessment

296 hat of wild-type CA assembly in complex with CypA.

297 d capsid binding by CypA and correlated with CypA linkage to the TRIM5a capsid-specificity determinan

298 esults, we propose that the interaction with CypA is independent of the ability of Vpr to induce cell

299 EC conditioned media, and preincubation with CypA augmented Ang II-induced vascular smooth muscle cel

300 kens the interaction of alpha-synuclein with CypA.